{"id":431367,"date":"2026-04-30T08:10:00","date_gmt":"2026-04-30T00:10:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=431367"},"modified":"2026-04-30T08:10:00","modified_gmt":"2026-04-30T00:10:00","slug":"%e6%ad%8c%e7%a6%ae%e5%b0%87%e6%94%9c%e5%a4%9a%e5%80%8b%e9%a0%85%e7%9b%ae%e6%95%b8%e6%93%9a%e4%ba%ae%e7%9b%b8%e7%be%8e%e5%9c%8b%e7%b3%96%e5%b0%bf%e7%97%85%e5%8d%94%e6%9c%832026%e5%b9%b4%e5%ba%a6","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=431367","title":{"rendered":"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u9999\u6e2f<\/span>2026\u5e744\u670830\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002<\/p>\n

\n<\/p><\/div>\n

\u5c55\u793a\u8a73\u60c5<\/b><\/p>\n

\u6a19\u984c\uff1a<\/b>ASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity)<\/p>\n

\u5834\u6b21\uff1a<\/b>\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB)<\/p>\n

\u65e5\u671f<\/b>\/<\/b>\u6642\u9593\uff1a<\/b>2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30<\/p>\n

\u6a19\u984c\uff1a<\/b>GLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity)<\/p>\n

\u5834\u6b21\uff1a<\/b>\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P)<\/p>\n

\u65e5\u671f<\/b>\/<\/b>\u6642\u9593\uff1a<\/b>2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30<\/p>\n

\u6a19\u984c\uff1a<\/b>ASC37\u53e3\u670d\u7247\uff08GLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies)<\/p>\n

\u5834\u6b21\uff1a<\/b>\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P)<\/p>\n

\u65e5\u671f<\/b>\/<\/b>\u6642\u9593\uff1a<\/b>2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30<\/p>\n

\u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703<\/a>\uff09\u3002<\/p>\n

\u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8<\/b><\/p>\n

\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002<\/p>\n

\u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com<\/span><\/a>\u3002<\/p>\n

\u8a73\u60c5\u5782\u8a62\uff1a<\/p>\n

Peter Vozzo
ICR Healthcare
443-231-0505 (\u7f8e\u570b)
Peter.vozzo@icrhealthcare.com<\/a>\u00a0<\/p>\n

\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a
+86-181-0650-9129 (\u4e2d\u570b)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a>\u00a0<\/p>\n

\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u9999\u6e2f2026\u5e744\u670830\u65e5 \/\u7f8e…<\/p>\n","protected":false},"author":16,"featured_media":431368,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-431367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"\n\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u9999\u6e2f2026\u5e744\u670830\u65e5 \/\u7f8e\u901a\u793e\/ -- \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002 \u5c55\u793a\u8a73\u60c5 \u6a19\u984c\uff1aASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity) \u5834\u6b21\uff1a\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aGLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aASC37\u53e3\u670d\u7247\uff08GLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff09\u3002 \u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002 \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com\u3002 \u8a73\u60c5\u5782\u8a62\uff1a Peter VozzoICR Healthcare443-231-0505 (\u7f8e\u570b)Peter.vozzo@icrhealthcare.com\u00a0 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a+86-181-0650-9129 (\u4e2d\u570b)pr@ascletis.com ir@ascletis.com\u00a0 \u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=431367\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u9999\u6e2f2026\u5e744\u670830\u65e5 \/\u7f8e\u901a\u793e\/ -- \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002 \u5c55\u793a\u8a73\u60c5 \u6a19\u984c\uff1aASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity) \u5834\u6b21\uff1a\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aGLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aASC37\u53e3\u670d\u7247\uff08GLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff09\u3002 \u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002 \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com\u3002 \u8a73\u60c5\u5782\u8a62\uff1a Peter VozzoICR Healthcare443-231-0505 (\u7f8e\u570b)Peter.vozzo@icrhealthcare.com\u00a0 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a+86-181-0650-9129 (\u4e2d\u570b)pr@ascletis.com ir@ascletis.com\u00a0 \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=431367\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T00:10:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1990\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\",\"datePublished\":\"2026-04-30T00:10:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367\"},\"wordCount\":163,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascletis_Pharma_Logo-2.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367\",\"name\":\"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascletis_Pharma_Logo-2.jpg\",\"datePublished\":\"2026-04-30T00:10:00+00:00\",\"description\":\"\u9999\u6e2f2026\u5e744\u670830\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002 \u5c55\u793a\u8a73\u60c5 \u6a19\u984c\uff1aASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity) \u5834\u6b21\uff1a\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB) \u65e5\u671f\\\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aGLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P) \u65e5\u671f\\\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aASC37\u53e3\u670d\u7247\uff08GLP-1R\\\/GIPR\\\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\\\/GIPR\\\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P) \u65e5\u671f\\\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff09\u3002 \u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\\\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\\\/GIPR\\\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002 \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com\u3002 \u8a73\u60c5\u5782\u8a62\uff1a Peter VozzoICR Healthcare443-231-0505 (\u7f8e\u570b)Peter.vozzo@icrhealthcare.com\u00a0 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a+86-181-0650-9129 (\u4e2d\u570b)pr@ascletis.com ir@ascletis.com\u00a0 \u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascletis_Pharma_Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Ascletis_Pharma_Logo-2.jpg\",\"width\":400,\"height\":154},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=431367#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u9999\u6e2f2026\u5e744\u670830\u65e5 \/\u7f8e\u901a\u793e\/ -- \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002 \u5c55\u793a\u8a73\u60c5 \u6a19\u984c\uff1aASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity) \u5834\u6b21\uff1a\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aGLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aASC37\u53e3\u670d\u7247\uff08GLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff09\u3002 \u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002 \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com\u3002 \u8a73\u60c5\u5782\u8a62\uff1a Peter VozzoICR Healthcare443-231-0505 (\u7f8e\u570b)Peter.vozzo@icrhealthcare.com\u00a0 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a+86-181-0650-9129 (\u4e2d\u570b)pr@ascletis.com ir@ascletis.com\u00a0 \u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=431367","og_locale":"zh_TW","og_type":"article","og_title":"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u9999\u6e2f2026\u5e744\u670830\u65e5 \/\u7f8e\u901a\u793e\/ -- \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002 \u5c55\u793a\u8a73\u60c5 \u6a19\u984c\uff1aASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity) \u5834\u6b21\uff1a\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aGLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aASC37\u53e3\u670d\u7247\uff08GLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff09\u3002 \u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002 \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com\u3002 \u8a73\u60c5\u5782\u8a62\uff1a Peter VozzoICR Healthcare443-231-0505 (\u7f8e\u570b)Peter.vozzo@icrhealthcare.com\u00a0 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a+86-181-0650-9129 (\u4e2d\u570b)pr@ascletis.com ir@ascletis.com\u00a0 \u00a0","og_url":"https:\/\/pingtungtimes.com.tw\/?p=431367","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2026-04-30T00:10:00+00:00","og_image":[{"width":3000,"height":1990,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=431367"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70","datePublished":"2026-04-30T00:10:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=431367"},"wordCount":163,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascletis_Pharma_Logo-2.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=431367","url":"https:\/\/pingtungtimes.com.tw\/?p=431367","name":"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascletis_Pharma_Logo-2.jpg","datePublished":"2026-04-30T00:10:00+00:00","description":"\u9999\u6e2f2026\u5e744\u670830\u65e5 \/\u7f8e\u901a\u793e\/ -- \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\uff08\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a1672\uff0c\u7c21\u7a31\u300c\u6b4c\u79ae\u300d\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u5c07\u57282026\u5e746\u67085\u65e5\u81f38\u65e5\u65bc\u8def\u6613\u65af\u5b89\u90a3\u5dde\u65b0\u5967\u723e\u826f\u8209\u884c\u7684\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff08ADA\uff092026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70\u4e0a\uff0c\u4ee5\u58c1\u5831\u5f62\u5f0f\u5c55\u793a\u591a\u500b\u9805\u76ee\u3002\u5c55\u793a\u5167\u5bb9\u5305\u62ecASC39\uff08\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u81e8\u5e8a\u524d\u6578\u64da\uff0c\u5176\u5165\u9078\u70ba\u6700\u65b0\u7a81\u7834\uff08late breaking\uff09\u58c1\u5831\u3002 \u5c55\u793a\u8a73\u60c5 \u6a19\u984c\uff1aASC39\uff1a\u4e00\u6b3e\u6cbb\u7642\u80a5\u80d6\u75c7\u7684\u985e\u4f3celoralintide\u3001\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291 (ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity) \u5834\u6b21\uff1a\u6700\u65b0\u7a81\u7834\u58c1\u5831\u5c08\u5834 (Late Breaking Poster Session) (3067-LB) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aGLP-1\u53e3\u670d\u5c0f\u5206\u5b50ASC30\u5728\u80a5\u80d6\u53d7\u8a66\u8005\u768413\u5468\u7f8e\u570bII\u671f\u7814\u7a76\u986f\u793a\u7d93\u5b89\u6170\u5291\u6821\u6b63\u5f8c\u7684\u9ad4\u91cd\u4e0b\u964d7.7%\uff0c\u4e14\u80c3\u8178\u9053\u8010\u53d7\u6027\u66f4\u4f73 (Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1672-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u6a19\u984c\uff1aASC37\u53e3\u670d\u7247\uff08GLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff09\u5728\u975e\u4eba\u9748\u9577\u985e\u52d5\u7269\u7814\u7a76\u4e2d\u5be6\u73fe4.2%\u7684\u5e73\u5747\u7d55\u5c0d\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6 (ASC37 Oral Tablets, GLP-1R\/GIPR\/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies) \u5834\u6b21\uff1a\u5468\u65e5\u5e38\u898f\u58c1\u5831\u5c08\u5834 (Sunday General Poster Session) (1673-P) \u65e5\u671f\/\u6642\u9593\uff1a2026\u5e746\u67087\u65e5\uff0c\u5468\u65e5\uff0c\u7f8e\u570b\u4e2d\u90e8\u6642\u9593 (CT) \u4e0b\u534812:30 \u95dc\u65bc2026\u5e74ADA\u79d1\u5b78\u6703\u8b70\u8a73\u60c5\uff0c\u53ef\u8a2a\u554fADA\u6703\u8b70\u7db2\u7ad9\uff08\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u6703\uff09\u3002 \u95dc\u65bc\u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8\u662f\u4e00\u5bb6\u5168\u50f9\u503c\u93c8\u6574\u5408\u578b\u751f\u7269\u6280\u8853\u516c\u53f8\uff0c\u805a\u7126\u6709\u671b\u6210\u70ba\u6cbb\u7642\u4ee3\u8b1d\u75be\u75c5\u540c\u985e\u6700\u4f73\uff08best-in-class\uff09\u548c\u540c\u985e\u9996\u5275\uff08first-in-class\uff09\u85e5\u7269\u7684\u958b\u767c\u548c\u5546\u696d\u5316\u3002\u5229\u7528\u516c\u53f8\u5c08\u6709\u7684\u57fa\u65bc\u7d50\u69cb\u7684AI\u8f14\u52a9\u85e5\u7269\u767c\u73fe\uff08Artificial Intelligence-assisted Structure-Based Drug Discovery\uff0cAISBDD\uff09\u3001\u8d85\u9577\u6548\u85e5\u7269\u958b\u767c\u5e73\u53f0\uff08Ultra-Long-Acting Platform\uff0cULAP\uff09\u6280\u8853\u4ee5\u53ca\u53e3\u670d\u591a\u80bd\u905e\u9001\u589e\u5f37\u6280\u8853\uff08Peptide Oral Transport ENhancement Technology\uff0cPOTENT\uff09\uff0c\u6b4c\u79ae\u5df2\u81ea\u4e3b\u7814\u767c\u591a\u6b3e\u5c0f\u5206\u5b50\u548c\u591a\u80bd\u5019\u9078\u85e5\u7269\uff0c\u5305\u62ec\u5176\u6838\u5fc3\u9805\u76eeASC30\uff0c\u4e00\u6b3e\u5728\u7814\u5c0f\u5206\u5b50GLP-1R\u6fc0\u52d5\u5291\uff0c\u65e2\u53ef\u6bcf\u65e5\u4e00\u6b21\u53e3\u670d\u4e5f\u53ef\u6bcf\u6708\u4e00\u6b21\u81f3\u6bcf\u5b63\u5ea6\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04\u4f5c\u70ba\u6e1b\u91cd\u6cbb\u7642\u7642\u6cd5\u548c\u6e1b\u91cd\u7dad\u6301\u7642\u6cd5\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\uff1bASC36\uff0c\u4e00\u6b3e\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC35\uff0c\u4e00\u6b3e\u6bcf\u6708\u4e00\u6b21\u76ae\u4e0b\u6ce8\u5c04GLP-1R\/GIPR\u96d9\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC37\uff0c\u4e00\u6b3eGLP-1R\/GIPR\/GCGR\u4e09\u9776\u9ede\u6fc0\u52d5\u5291\u591a\u80bd\uff0cASC39\uff0c\u4e00\u6b3e\u985e\u4f3celoralintide\u3001\u5c0d\u80f0\u6fb1\u7d20\u5177\u6709\u9078\u64c7\u6027\u7684\u5f37\u6548\u53e3\u670d\u5c0f\u5206\u5b50\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff0c\u548cASC30_39 FDC\uff0cASC30\uff08GLP-1RA\uff09\u8207ASC39\uff08\u80f0\u6fb1\u7d20\u53d7\u9ad4\u6fc0\u52d5\u5291\uff09\u7684\u56fa\u5b9a\u5291\u91cf\u5fa9\u65b9\u5236\u5291\uff08FDC\uff09\uff0c\u7528\u65bc\u9577\u671f\u9ad4\u91cd\u7ba1\u7406\u3002\u6b4c\u79ae\u5df2\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e0a\u5e02\uff081672.HK\uff09\u3002 \u6b32\u4e86\u89e3\u66f4\u591a\u4fe1\u606f\uff0c\u656c\u8acb\u767b\u9304\u7db2\u7ad9\uff1awww.ascletis.com\u3002 \u8a73\u60c5\u5782\u8a62\uff1a Peter VozzoICR Healthcare443-231-0505 (\u7f8e\u570b)Peter.vozzo@icrhealthcare.com\u00a0 \u6b4c\u79ae\u5236\u85e5\u6709\u9650\u516c\u53f8PR\u548cIR\u5718\u968a+86-181-0650-9129 (\u4e2d\u570b)pr@ascletis.com ir@ascletis.com\u00a0 \u00a0","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=431367"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascletis_Pharma_Logo-2.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/04\/Ascletis_Pharma_Logo-2.jpg","width":400,"height":154},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=431367#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u6b4c\u79ae\u5c07\u651c\u591a\u500b\u9805\u76ee\u6578\u64da\u4eae\u76f8\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5354\u67032026\u5e74\u5ea6\u79d1\u5b78\u6703\u8b70"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/431367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=431367"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/431367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/431368"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=431367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=431367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=431367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}